MAATClinical Trials•businesswire•
MaaT Pharma Presents Updated Positive Data in Early Access Program for Xervyteg® at the EHA Congress Validating High Efficacy Observed in Pivotal ARES Study in Acute Graft-versus-Host Disease
Sentiment:Positive (80)
Summary
LYON, France--(BUSINESS WIRE)---- $MAAT #Cancer--MaaT Pharma Presents Updated Positive Data in Early Access Program for Xervyteg® at the EHA Annual Congress.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on June 13, 2025 by businesswire